TNFRSF8 and Hodgkins lymphoma: Similarly, therapies that target CD30 have already shown efficacy in clinical settings, as evidenced by the success of brentuximab vedotin, an antibody–drug conjugate targeting CD30, which has demonstrated significant responses in patients with relapsed or refractory HL [25,30].